Story perspectives

aTyr Pharma Shares Plummet After Trial Setback

9/15/2025

23 2

Summary

Story summary

aTyr Pharma's efzofitimod failed to achieve its primary goal in a Phase 3 trial for pulmonary sarcoidosis, resulting in an 80% drop in shares.
The trial indicated a reduction in steroid use from 3.52 mg/day (placebo) to 2.79 mg/day (efzofitimod), but this difference lacked statistical significance.
CEO Sanjay Shukla mentioned that patients reported feeling better, indicating potential for efzofitimod as maintenance therapy.
aTyr plans to consult with the FDA regarding the trial results and future steps.
Analysts remain skeptical about the drug's prospects due to unclear benefits and challenging future trials.

1 of 1

Story summary

aTyr Pharma's efzofitimod failed to achieve its primary goal in a Phase 3 trial for pulmonary sarcoidosis, resulting in an 80% drop in shares.
The trial indicated a reduction in steroid use from 3.52 mg/day (placebo) to 2.79 mg/day (efzofitimod), but this difference lacked statistical significance.
CEO Sanjay Shukla mentioned that patients reported feeling better, indicating potential for efzofitimod as maintenance therapy.
aTyr plans to consult with the FDA regarding the trial results and future steps.
Analysts remain skeptical about the drug's prospects due to unclear benefits and challenging future trials.